# Anteris Technologies Global Corp.: overview

AVR · Nasdaq · CIK 2011514 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/avr.md) · [Financials](/companies/avr/financials.md) · [Filings](/companies/avr/filings.md) · [Insiders](/companies/avr/insiders.md)

Latest reported revenue: [$1.0m](/filings/0001140361-26-032232.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001140361-26-032232).

## Last eight quarters

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.8](/filings/0001140361-25-041643.md) | [0.5 d](/filings/0001140361-26-006977.md) | [0.6](/filings/0001140361-26-020806.md) | [0.6](/filings/0001140361-26-032232.md) | [0.4](/filings/0001140361-25-041643.md) | [0.3 d](/filings/0001140361-26-006977.md) | [0.5](/filings/0001140361-26-020806.md) | [1.0](/filings/0001140361-26-032232.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(2678.4%)](/filings/0001140361-25-041643.md) | [(4014.7%) d](/filings/0001140361-26-006977.md) | [(3917.3%)](/filings/0001140361-26-020806.md) | [(3379.3%)](/filings/0001140361-26-032232.md) | [(5190.0%)](/filings/0001140361-25-041643.md) | [(9343.5%) d](/filings/0001140361-26-006977.md) | [(4859.7%)](/filings/0001140361-26-020806.md) | [(3072.1%)](/filings/0001140361-26-032232.md) |
| Net margin | % | [(2842.4%)](/filings/0001140361-25-041643.md) | [(3614.9%) d](/filings/0001140361-26-006977.md) | [(3932.4%)](/filings/0001140361-26-020806.md) | [(3371.2%)](/filings/0001140361-26-032232.md) | [(5185.1%)](/filings/0001140361-25-041643.md) | [(9420.0%) d](/filings/0001140361-26-006977.md) | [(4660.7%)](/filings/0001140361-26-020806.md) | [(2883.4%)](/filings/0001140361-26-032232.md) |
| Diluted EPS | $ per share | [(1.07)](/filings/0001140361-25-041643.md) | not reported | [(0.61)](/filings/0001140361-26-020806.md) | [(0.58)](/filings/0001140361-26-032232.md) | [(0.62)](/filings/0001140361-25-041643.md) | not reported | [(0.28)](/filings/0001140361-26-020806.md) | [(0.30)](/filings/0001140361-26-032232.md) |
| Free cash flow | $m | [(14.6) d](/filings/0001140361-25-041643.md) | [(18.6) d](/filings/0001140361-26-006977.md) | [(21.7)](/filings/0001140361-26-020806.md) | [(20.1) d](/filings/0001140361-26-032232.md) | [(19.0) d](/filings/0001140361-25-041643.md) | [(18.9) d](/filings/0001140361-26-006977.md) | [(28.8)](/filings/0001140361-26-020806.md) | [(21.4) d](/filings/0001140361-26-032232.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: |
| Revenue | $m | [2.7](/filings/0001140361-26-006977.md) | [1.9](/filings/0001140361-26-006977.md) |
| Gross margin | % | not reported | not reported |
| Operating margin | % | [(2899.4%)](/filings/0001140361-26-006977.md) | [(4908.2%)](/filings/0001140361-26-006977.md) |
| Net margin | % | [(2822.5%)](/filings/0001140361-26-006977.md) | [(4921.3%)](/filings/0001140361-26-006977.md) |
| Diluted EPS | $ per share | [(3.68)](/filings/0001140361-26-006977.md) | [(2.55)](/filings/0001140361-26-006977.md) |
| Free cash flow | $m | [(63.5)](/filings/0001140361-26-006977.md) | [(79.8)](/filings/0001140361-26-006977.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/avr/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [L1 Capital Pty Ltd](/funds/1817646.md) | 2026-06-30 | $76.7m | 7,789,000 |  | Unchanged |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $67.7m | 6,868,086 |  | Added +3,966,736 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $56.8m | 5,771,213 |  | Added +882,060 |
| [Sio Capital Management, LLC](/funds/1482416.md) | 2026-06-30 | $54.6m | 5,545,984 |  | Added +163,019 |
| [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $33.7m | 3,425,476 |  | Unchanged |
| [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $33.3m | 3,383,335 |  | Reduced −2,147,575 |
| [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $33.3m | 3,383,335 |  | Reduced −2,147,575 |
| [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $31.0m | 3,145,096 |  | Reduced −644,036 |
| [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $29.6m | 3,000,000 |  | Unchanged |
| [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $29.6m | 3,000,000 |  | Unchanged |

## Recent filings

[All 184 filings](/companies/avr/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-23 | 07:30 ET | [8-K](/filings/0001140361-26-037392.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001140361-26-037392 |
| 2026-09-17 | 17:00 ET | [8-K](/filings/0001140361-26-037002.md) | 5.02 Departure or appointment of officers or directors | 0001140361-26-037002 |
| 2026-09-08 | 07:01 ET | [8-K](/filings/0001140361-26-035840.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001140361-26-035840 |
| 2026-08-12 | 19:07 ET | [8-K](/filings/0001140361-26-032296.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-032296 |
| 2026-08-11 | 16:05 ET | [10-Q](/filings/0001140361-26-032232.md) | Quarterly report, period 2026-06-30 | 0001140361-26-032232 |
| 2026-08-03 | 09:05 ET | [8-K](/filings/0001140361-26-030586.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-030586 |
| 2026-07-31 | 08:38 ET | [8-K](/filings/0001140361-26-030355.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-030355 |
| 2026-05-22 | 17:15 ET | [8-K](/filings/0001140361-26-022633.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001140361-26-022633 |
| 2026-05-13 | 20:55 ET | [8-K](/filings/0001140361-26-020901.md) | 5.02 Departure or appointment of officers or directors | 0001140361-26-020901 |
| 2026-05-13 | 20:39 ET | [8-K](/filings/0001140361-26-020896.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-020896 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001140361-26-006977.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/25d250a5-d2de-412b-b2e7-23562e5d4889)

## About the filer

- CIK: 2011514
- Tickers: AVR
- Exchange: Nasdaq
- SIC code: 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 09:01 ET. No prices; not investment advice.